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Abstract
Introduction Biomarkers for early detection of renal cell
carcinoma (RCC) may help diagnose minimal residual
disease in patients at risk for RCC, can guide anti-
angiogenic therapy, or may help identify candidates for
adjuvant treatment. In this study, we investigated whether
blood levels of carbonic anhydrase 9 (CA9) correlate with
RCC tumor burden and therefore disease activity.
Methods CA9 is a von Hippel–Lindau–hypoxia inducible
factor target upregulated in clear cell RCC. We used an
anti-CA9 antibody (M75)-based enzyme-linked immuno-
sorbent assay test to measure CA9 levels in blood obtained
before and after nephrectomy for clinically localized
disease in patients with: (1) clear cell RCC, (2) papillary
and chromophobe RCC or oncocytoma, or (3) benign
kidney lesions, and we compared these samples to blood
drawn from normal control individuals.
Results We observed a significant (p<0.006) decrease in
the blood levels of CA9, after nephrectomy for localized
disease, in the majority of patients with clear cell RCC
(57%). In contrast, patients with nonclear cell RCC, benign
disease, or those having undergone debulking nephrectomy
for metastatic disease did not have a decrease in CA9 blood
levels after nephrectomy. Preliminary longitudinal follow
up measurements of CA9 levels in a small group of patients
indicated that rising CA9 levels may correlate with disease
progression.
Conclusions Plasma CA9 levels correlate with disease
activity in a subset of clear cell RCC patients and should
be considered in future multiplex RCC biomarker develop-
ment algorithms.
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Introduction
The incidence of renal cell carcinoma (RCC) has steadily
risen in the United States since 1970 and is currently
estimated at approximately 51,000 cases per year. This
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increase has been observed across gender and race,
increasing among black males and females by 3.9% and
4.3% per year, and white males and females by 2.3% and
3.1% per year, respectively [1]. The majority of sporadic
clear cell carcinoma is of clear cell histology (75%),
followed by papillary type I (5%) and type II (5%), as well
as chromophobe and oncocytoma (15%). It is clear that
distinct molecular mechanisms underlie each histologic
type [2].
Organ-confined disease is treated with surgery. The 5-
year survival rate for patients presenting with stage I
disease is 95%, while the survival rate for patients with
stage II and III RCC is decreased to 70–80% and 40–60%,
respectively [3]. It is therefore reasonable to assume that
early disease detection would improve overall survival in
RCC patients.
Medical treatment of clear cell RCC patients has been
evolving rapidly. Understanding of the von Hippel–Lindau
(VHL) signaling pathway and its deregulation during clear
cell RCC development has led to the identification of
rational molecular therapeutic targets. Clinical trials with
small molecule inhibitors of the vascular endothelial growth
factor, platelet-derived growth factor, and other receptor or
nonreceptor cellular kinases, such as mammalian target of
rapamycin, show promising results [4–9].
Targeted therapy has opened a new set of possibilities
and questions in RCC treatment. Tumor response by
classical imaging criteria fails to reflect changes in tumor
vessel density, tumor viability, or correlate with disease
progression or even overall survival. The availability of
biomarkers that reflect disease activity may therefore help
guide therapy. Biomarkers that serve as surrogate markers
of tumor response will expedite a large number of clinical
trials in which kinase inhibitors are used in combination in
patients both pre- and postsurgery. Treatment of patients
with minimal residual disease may prove, now that
effective therapies are available, to be a better approach
than treatment following clinical detection. Adjuvant trials
may target patients with biomarker-detected minimal
residual disease after nephrectomy for the primary tumor.
Many laboratories are therefore interested in the discov-
ery and validation of specific and sensitive biomarkers of
disease activity in the blood and/or urine of RCC patients.
Here, we examined the expression of carbonic anhydrase 9
(CA9) as a potential circulating blood biomarker of clear cell
RCC activity. The majority of clear cell renal cell cancers are
deficient in VHL function and they are characterized by
upregulation of hypoxia inducible transcription factors (HIF)
1a and HIF2a. CA9 is a transmembrane glycoprotein
involved in regulation of extracellular and intracellular pH.
CA9 is a direct target of HIF1a and is greatly upregulated in
primary and metastatic RCC lesions [10, 11]. CA9 has a
restricted pattern of expression in normal tissues; it is
detected in the epithelium of the stomach, gallbladder, and
exocrine pancreas. Retrospective analysis of patients treated
with high-dose interleukin (IL)-2 indicated that CA9 may
predict response to this therapy [12–14] and gene expres-
sion levels of CA9 in primary tumor may correlate with
higher risk for metastasis [14].
Because CA9 is linked to hypoxia–HIF–VHL signaling
and appears to have a restricted expression pattern in adult
tissue, we decided to investigate its value as a blood
circulating biomarker for RCC by measuring CA9 expres-
sion in the plasma/serum of patients with clinically
localized disease pre- and postnephrectomy. To the best of
our knowledge, this is the first circulating biomarker
reported to decrease in the blood of RCC patients after
nephrectomy and/or to correlate with changes in tumor
burden.
Materials and Methods
Cell Lines and Culture
The human RCC cell lines 786-O, UMRC2, UMRC3, and
UMRC6 (obtained through American Type Culture Collec-
tion) lack wild-type VHL. Parental cell lines were used to
derive isogenic clones stably expressing hemagglutinin
(HA)-VHL30 or VHL-19 or harboring empty pRC/CMV
plasmid as a control. Transfections were performed with
Lipofectamine 2000 using manufacturer’s instructions and
clones were generated by neomycin selection. Cells were
grown in Dulbecco’s modified Eagle’s medium (Media
Tech) with 10% fetal clone (Hyclone Laboratories) plus one
times penicillin–streptomycin–glutamine solution (100×;
Invitrogen Life Sciences), supplemented with neomycin at
the appropriate concentration for each cell line.
RNA Extraction/qRT-PCR
Normal human RNA control samples were obtained from
Stratagene. The tissues included kidney, liver, brain, skin,
and spleen. RNA was isolated from cells at 80–90%
confluence. RNA was isolated using 6 mL of TRI Reagent
LS (Molecular Research Center) and purified over RNeasy
Mini Kit columns (Qiagen) and eluted into 30 μL of diethyl
pyrocarbonate-treated distilled water. RNA (1 μg total) was
reverse transcribed to cDNA using Super Script III
(Invitrogen) according to manufacturer’s protocol.
Quantitative real-time polymerase chain reaction (qRT-
PCR) was performed per the manufacturer’s recommenda-
tions using the SYBR Green Detection System (BioRad).
Intron spanning primers for CA9 were designed (forward:
5′-GAGGATCTACCTGGAGAGGA-3′; reverse: 5′-CTGG
AAGCCCAGGAGTTCCA-3′). Quantitation of B-globulin
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(forward 5′-TTT CAT CCA TCC GAC ATT GA-3′;
reverse: 5′-ATC TTC AAA CCT CCA TGA TG-3′) was
performed and used for normalization of gene expression
data. Each sample was run in triplicate. RNA sample
without RT polymerase was used as a negative control. All
PCR products were sequenced to confirm the identity of the
amplified gene.
Microarray Analysis
RNA extraction and cDNA generation from RCC frozen
tissue samples for gene expression profiling using HG-
U133A Affymetrix GeneChips has been previously de-
scribed [15].
Western Blot Analysis
Cells were washed twice with ice cold phosphate buffered
saline and lysed in radio-immunoprecipitation assay buffer
(50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5%
deoxycholate, 0.1% sodium dodecyl sulfate (SDS), and
0.02% NaN3) supplemented with proteinase inhibitors
(20 μg/mL trypsin inhibitor, 10 μg/mL leupeptin, 200 μM
NaOrthovanadate, 5 μg/mL pepstatin A, 20 μg/mL aproti-
nin, 100 mM NaF, and 200 μg/mL phenylmethylsulphonyl
fluoride). Protein concentration was estimated by the
Bradford method. Proteins were resolved (BioRad) by
SDS-polyacrylamide gel electrophoresis and transferred
onto polyvinylidene fluoride membrane (BioRad) for
immunoblotting.
Antibodies
Antibodies for Western blot were used at indicated dilutions:
anti-HIF-2a polyclonal (Novus NB100–122, 1:1,000), anti-
actin monoclonal (Abcam Ab8226, 1:1,000), anti-HA
monoclonal (Abcam, 12CA5, 1:1,000), anticarbonic anhy-
drase 9 monoclonal (M75, gift from Novartis, 1:3,000).
Secondary horseradish peroxidase-conjugated antibodies to
mouse or rabbit IgG were purchased from Pierce and
detected by Western Lighting Chemiluminescence Reagent
Plus (Perkin Elmer, NEL105) according to the manufac-
turer’s protocol.
ELISA
Enzyme-linked immunosorbent assay (ELISA) of human
plasma or serum for carbonic anhydrase 9 was performed in
triplicate using the commercially available MN/CAIX
ELISA kit (Siemens Diagnostics). Solid phase sandwich
ELISA was performed per manufacture’s protocol which
has an analytic range of 0 to 1,500 pg/mL and a sensitivity
of 2.5 pg/mL per product literature.
Human Sample Collection
Plasma, serum, and urine from patients with renal cell
carcinoma have been collected, under prior Institutional
Review Board approved protocol, before nephrectomy for
localized disease and at regular intervals following ne-
phrectomy. Blood samples were then centrifuged at
3,500 rpm, aliquoted, and stored at −80°C until processing.
Tumor samples were frozen and stored after pathology
evaluation to determine histological subtyping. All patients
provided informed consent for tumor and blood sample
collection.
Results
Loss-of-VHL function and constitutive upregulation of the
transcription factor hypoxia inducible factor is the earliest
known molecular event in the majority of clear cell RCC.
Reconstitution of the VHL function by stable reintroduction
of VHL (either the 30 or 19 kDa isoform) or inactivation of
the HIF protein leads to growth suppression of these cell
lines as tumors in the xenograft assay [16–18]. These
observations indicate that the fundamental signaling path-
ways implicated in renal carcinogenesis are intact in these
cell lines. In order to identify candidate biomarkers for
RCC, we compared the gene expression profile of human
renal cell carcinoma cell lines that are deficient in VHL
tumor suppressor protein to their isogenic counterparts that
stably express VHL.
One of the messages upregulated by loss-of-VHL
function, as measured by DNA microarray, was the
transmembrane glycoprotein carbonic anhydrase 9. To
validate the microarray data and to test whether differences
at the mRNA level reflect differences in protein expression
in various cell lines, we examined CA9 mRNA and protein
expression in human RCC cell lines under identical culture
conditions. CA9 protein expression was analyzed by
Western blot (Fig. 1a) in VHL deficient cell lines 786-O,
UMRC2, and UMRC6 (lanes 1, 3, and 5 of Fig. 1a) and
their corresponding isogenic clones that express VHL30 or
VHL19 (Fig. 1a, lanes 2, 4, and 6). CA9 mRNA expression
was examined by qRT-PCR (Fig. 1b). The high expression
of the CA9 message in UMRC2 cells (Fig. 1b, lane 3)
corresponds to a robust signal for CA9 in Western blot
analysis (Fig. 1a, lane 3), while the much weaker mRNA
expression in lines 786-O and UMRC6 (Fig. 1b, lanes 1
and 5) resulted in no detectable protein (Fig. 1a, lanes 1 and
5). These experiments encouraged us to interrogate the
expression of CA9 in matched tumor–normal tissue
samples as well as adult normal tissues.
To this end, we compared the expression of CA9 by
oligonucleotide microarray in ten specimens of clear cell
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RCC tumor (T) to matched normal renal parenchyma (N)
obtained from the same individuals. CA9 was upregulated
in all RCC specimens compared to normal matched tissue
(Fig. 1c, A). Moreover, there was essentially no overlap
between absolute values of mRNA signal detected in RCC
tumors (T) compared to normal matched parenchyma (N;
Fig. 1c, B).
Changes in circulating levels of a biomarker attributed to
the presence of RCC may be potentially masked because of
its pleiotropic expression in other tissues. Organ-restricted



























































































































































































Fig. 1 Expression of carbonic anhydrase 9 (CA9) in human renal cell
carcinoma cell lines and tumors. a Cell lysates of clones derived from
human renal cell carcinoma cell lines 786-O, UMRC2, and UMRC6
stably transfected with vector control plasmid (lanes 1, 3, and 5) or
plasmids expressing VHL30 (lanes 2a and 4) or VHL19 (lane 6) were
immunoblotted for HIF1a, HIF2a, VHL, and CA9 as indicated. Actin
was used as loading control. b qRT-PCR of CA9 message from same
cell lines. c, A Fold increase of CA9 in clear cell human RCC tumor
(T) compared to normal (N) matched kidney tissue. c, B Absolute
values of expression of CA9 in RCC tumor (T) compared to normal
(N) matched kidney tissue. d Relative tissue expression of CA9 in
adult human tissues
Fig. 2 Changes in blood levels of CA9 in patients having undergone
curative nephrectomy for localized clear cell RCC. a MGH patients:
patient sex, disease stage, tumor volume, and plasma levels of CA9
before (PRE) or after (POST) nephrectomy are listed. b Correlation
between tumor volume and preoperative levels of CA9 (expressed in
log scale) in the MGH patient group. c MDACC patients: patient sex,
disease stage, tumor volume, and serum levels of CA9 before (PRE)
or after (POST) nephrectomy. d Correlation between tumor volume
and preoperative levels of CA9 (expressed in log scale) in the serum
of MDACC patient group. e Blood levels of CA9 before and after
nephrectomy for localized RCC in all patients from the two
institutions (MGH and MDACC)

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Pt ID SEX PRE POST Tumor volume
87 M 348.12 277.23 25.625
83 F 119.81 30.35 61.38
93 M 155.22 197.62 33.75
103 F 315.10 266.71 150
104 M 381.26 154.65 67.5
28 F 61.92 146.20 86.625
46 M 400.79 488.14 142.5
58 M 777.79 366.72 263.9
64 F 137.33 124.63 34.848
137 F 319.24 259.14 44
146 M 201.90 208.27 36
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13 124.62 101.71 39.90
18 72.16 45.36 46.20
19 259.36 32.52 144.00
22 66.48 23.80 783.00
23 2055.16 1465.34 864.00
27 61.84 67.00 234.00`
29 151.83 133.50 472.50
34 90.80 144.49 186.48
35 19.20 6.93 18.00
39 19.99 0.10 30.00
40 197.35 0.10 476.00
42 506.86 260.04 688.50
43 292.11 427.35 135.00
51 455.93 204.23 1026.00
53 31.75 20.61 14.20
54 52.21 89.46 37.44
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detection of incremental changes that correlate with tumor
volume. We therefore examined the expression of CA9 by
qRT-PCR in total RNA extracted from various adult tissues
(Fig. 1d). CA9 was highly expressed in human adult brain
compared to the other organs examined. Skin and liver,
which are bulky organs, showed weak expression of CA9.
In keeping with previous literature reports and our own
microarray data, CA9 expression was very low in normal
adult kidney.
To examine weather circulating CA9 levels correlated
with RCC disease activity, we first measured the levels of
this potential biomarker in the plasma of RCC patients with
localized disease. Samples were obtained both prior to
nephrectomy and between 6–8 weeks postsurgery.
Figure 2a presents patient sex and tumor volume at a
single institution (Massachusetts General Hospital, MGH)
and circulating CA9 levels prior to (pre) and after (post)
nephrectomy. Measurements were obtained with a com-
mercially available CA9 ELISA kit (Siemens Diagnostics
Inc.). The manufacturer reports and we independently
confirmed, an 10% intra-assay variability. Thus, only
changes greater than 10% in either direction were regarded
as significant. All measurements were done in triplicate and
the reported values are the mean. All tumors reported in
Fig. 1 are clear cell carcinomas. Six out of 12 patients
(50%) had a decrease in postoperative values of CA9
(50%). In three out of 12 patients (25%), there was an
increase, and the remaining three patients (25%) had no
significant difference. Although this is a small group of
patients, preoperative values correlated with tumor volume
(Fig. 2b; r2=0.77). To evaluate the impact of a volume
“threshold” on the formation of this correlation, we remove
patient 58 from the MGH group (this is the patient with the
highest tumor volume). In this case, the r2 value is reduced
to 0.41. On the other hand, if we remove patient MGH 87
(the one with the smallest tumor volume), r2 improves to
0.83.
To test whether these changes reflected any institutional
bias and to further expand the tested population, we
obtained samples of patients independently collected using
a similar protocol (the exception being that serum was
banked instead of plasma) at a second institution (MD
Anderson Cancer Center, MDACC). We observed no
significant difference between measurements of CA9 in
plasma and serum. Figure 2c describes the MDACC patient
sample and the CA9 values prior to and after nephrectomy.
CA9 values decreased in 60% (21 out of 35) of MDACC
patients postnephrectomy, while there was no change in
15% (five of 35) of patients and an increase in 25% (nine of
35). The correlation between preoperative CA9 values and
tumor volume in this population was less than in the MGH
population (Fig. 2d; r=0.42). To evaluate the impact of
single points in the formation of this correlation, we
removed patient MDACC 23, in which case the r2 drops
to 0.32. On the other hand, by removing MDACC 7, the
single patient that despite the high tumor volume produces
little CA9, the r2 value improves to 0.52. Our interpretation
is that CA9 levels reflect to a certain degree of the tumor
volume. Future studies with a larger patient population will
be necessary to establish a precise correlation statistic to
better characterize the relationship between CA9 blood
levels and the presence of tumor.
Analyzed together, the data from both institutions
indicate that in a subset of patients with localized clear cell
RCC (57%) undergoing curative nephrectomy, there is a
decrease in the circulating levels of CA9 postoperatively.
Comparison of preoperative to postoperative blood levels
of CA9 in the combined MGH and MDACC patients
demonstrates a significant decrease in CA9 levels (p-value
is 0.0097, and the preoperative values are significantly
higher than the postoperative values, with a 95% confi-
dence interval of (6.7–81.8) and a median estimate of
32.3 pg/mL, shown in Fig. 2e).
In contrast to patients with clear cell histology, patients


































Fig. 3 Blood CA9 levels in nonclear cell kidney lesions and normal
controls. a Changes in plasma levels of CA9 in patients undergoing
nephrectomy for benign renal lesions or RCC of nonclear histology.
Pre indicates blood CA9 levels prior to surgery and Post indicates the
CA9 blood levels 4–5 weeks after nephrectomy. b Comparison of
plasma levels of CA9 between RCC patients at presentation (RCC)
and an independent set of normal control individuals (Control).
Horizontal bars indicate median values (in pg/mL)
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nonclear cell RCC histology did not have a significant
decrease in plasma CA9 levels (Fig. 3a). Additionally, we
measured CA9 in the plasma of patients without known
RCC, as a sample of “normal control” individuals; there is
considerable overlap of CA9 plasma values in normal
controls and RCC patients prior to nephrectomy (Fig. 3b).
To examine whether blood levels of CA9 correlate with
disease activity over time and/or herald a local or systemic
relapse of disease, we measured circulating CA9 levels in
available plasma samples of clear cell RCC patients
following curative or debulking nephrectomy (Fig. 4;
Table 1). Patients 104, 139, and 146 remained disease-free
at the indicated time of follow-up and their longitudinal
CA9 plasma levels did not rise above post- or preoperative
levels. Patients 176, 186, 113, and 136 presented with
metastatic disease and underwent debulking nephrectomy.
It is notable that in the three patients that can be evaluated,
the postoperative levels of CA9 did not decline. Patient 186
responded to treatment and the clinical response correlated
with a marked decline in CA9 plasma levels. Patients 176,
186, 113, and 136 had either stable disease under treatment
with anti-angiogenic agents or disease progression. In the
latter case, plasma levels of CA9 rose steadily.
Discussion
Our data demonstrate that circulating blood levels of CA9,
a transcriptional target of HIF activity, declined in approx-
imately 60% of clear cell RCC patients who underwent
curative nephrectomy for organ-confined disease. RCC
patients with nonclear cell histology or benign tumors had
no change in CA9 plasma levels. Preoperative levels of
CA9 correlated with tumor volume in patients with
localized disease. None of the patients that presented with
clinically overt metastatic disease and underwent debulking
nephrectomy had a decrease in postoperative CA9 plasma
levels. Moreover, follow-up measurements of CA9 plasma
levels correlated with tumor progression or response to
therapy in the small group of patients we examined.
CA9 levels decreased postoperatively in a defined subset
of patients with localized disease. At this point, we do not
know the common denominator that defines this patient
subset. Several testable hypotheses that take into consider-
ation our current knowledge of RCC biology could explain
this heterogeneity. Loss-of-VHL function occurs in approx-
imately 55–70% of patients with sporadic RCC, while the
































Fig. 4 Longitudinal measurements of plasma levels of CA9 in
patients with clear cell RCC undergoing curative or debulking
nephrectomy. SU Treatment with suten, G treatment with gemcitabine,
PR partial response, SD stable disease, DP disease progression, NED
no evidence of disease. Specific values and times of blood collection
are provided in Table 1
Table 1 Longitudinal measurements of plasma levels of CA9 in patients with clear cell RCC undergoing curative or debulking nephrectomy
Patient Sex Pre Post 6 months 12 months 2 years Stage Follow-up
104 M 381.26 154.65 201.2812444 pT1b Nx Mx NED 5/10/07
4/21/2005 6/23/2005 5/10/2007
176 M 431.69 751.74 1,087.08 T1bN2M1 Tx with SU/DP
12/13/06 2/15/07 Post 5/10/07
186 M No pre 430.28 70.55 52.43 T3bN2M0, DN-1/07 Tx with SU+G/PR
2/27/07 Post 4/19/07 Post 5/10/07
113 M 394.42 359.81 860.55 T2N2M1 on presentation Tx with SU/SD
7/8/05 8/22/05 3/29/07
136 F 1,032.19 1,035.50 2,711.44 2,855.51 T3aN0M1 SU (6/06)/SD
3/30/2006 5/11/2006 10/24/2006 2/27/2007
139 F 143.28 201.90 T3aN0M0 NED (12/06)
5/1/06 12/19/2006
146 M 201.90 208.27 203.17 T1bN0M0 NED
6/8/2006 8/24/2006 1/16/2007
SU Treatment with sutent, G treatment with gemcitabine, PR partial response, SD stable disease, DP disease progression, NED no evidence of
disease
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addition, patients with clear cell RCC may be divided in
“high” and “low” expressers of CA9 by immunocytochem-
istry of the tumor. It is possible that circulating levels of
CA9 is a sensitive marker of disease activity only for VHL-
associated RCC patients or for the high CA9 expressers. It
is also formally possible that clearance of CA9 from the
circulation has different kinetic properties among individual
patients, although a reasonable time interval (4 weeks at
least) was allowed between pre- and postnephrectomy
measurements. Lastly, it is interesting to note that CA12,
another member of the CA family, is also overexpressed in
clear cell RCC, albeit in a lower percentage of patients than
CA9. It is possible that for a subset of patients CA12 is a
more reliable marker for disease activity than CA9. We are
currently developing an ELISA assay for CA12 to test this
hypothesis. The observation that CA9 scores for only a
subset of RCC patients emphasizes the need to discover and
validate a panel of biomarkers for RCC activity. This
heterogeneity may also explain the variability in the
correlation between tumor volume and CA9 blood levels.
This correlation may, to a certain degree, be attenuated by
the presence of low expressing tumors, independent of size.
However, the presence of a relative correlation in this small
patient population demonstrates the link between circulat-
ing blood levels of CA9 and its source of origin.
All patients with disease progression had increased CA9
plasma levels, above that observed post- or preoperatively.
One patient treated for systemic disease had a partial
clinical response that correlated with reduced CA9 levels. It
is therefore possible that, for a given population of RCC
patients, fluctuation in CA9 levels over time may be a
useful biomarker for early detection of tumor response or
impeding disease relapse/progression. These data are
clearly preliminary and large datasets are clearly required
in order to incorporate changes in CA9 blood levels into
clinical decision making. Our current data aim to highlight
that CA9 should be considered and evaluated as a potential
biomarker of RCC response to treatment. Alternatively,
preoperative or postoperative levels of CA9 may have
prognostic value and may be a useful independent factor for
predicting disease free or overall survival.
Few biomarkers for RCC have been previously proposed
in small patient samples. Of those, kidney injury molecule-
1 (KIM-1), a transmembrane glycoprotein upregulated in
ischemic injury of the kidney epithelium, was reported to
be elevated in RCC tumors and in the urine of RCC patients
compared to normal controls [19]. No measurements of
KIM-1 in the blood of RCC patients before or following
nephrectomy have been reported so far. Elevated levels of
nuclear matrix protein 22 (NMP22) has been detected in the
urine of patients with RCC and a follow-up study indicated
that specificity and sensitivity of RCC diagnosis ranged at
55% [20]. No data for blood levels of NMP22 have been
reported. Matrix metalloproteinase activity has also been
reported to be elevated in the urine of RCC patients [21].
Other reported biomarkers of RCC in the blood include a
tumor-specific isoform of pyruvate kinase (TuPK; a HIF
target) as well as plasma levels of IL-6, tumor necrosis
factor α, and circulating mRNA levels of prostate specific
membrane antigen [22–25]. Few of these biomarkers have
limited specificity and may reflect a systemic response to
tumor burden. Others such as KIM-1, TuPK, and NMP22
could be incorporated into larger clinical studies evaluating
the performance of a group of disease specific biomarkers
[26].
In summary, we used gene expression comparison of
signaling dependent human renal cell carcinoma cell lines
to identify potential circulating biomarkers for clear cell
RCC. We measured CA9 blood levels and demonstrated a
correlation with the presence of disease in a subset of clear
cell RCC patients. To the best of our knowledge, this is the
first report of blood changes in a potential RCC biomarker
postnephrectomy for localize RCC disease. Larger studies
for definitive validation and clinical characterization of
CA9 will be needed. The data presented herein supports
this larger testing and underscores the need for discovery
and validation of a panel of biomarkers that will globally
reflect RCC disease activity.
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